224 related articles for article (PubMed ID: 9057699)
21. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
Tonui WK; Titus RG
Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
[TBL] [Abstract][Full Text] [Related]
22. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
Bhardwaj S; Vasishta RK; Arora SK
Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
[TBL] [Abstract][Full Text] [Related]
24. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
Badiee A; Jaafari MR; Khamesipour A
Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
[TBL] [Abstract][Full Text] [Related]
25. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
Scott P; Pearce E; Natovitz P; Sher A
J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599
[TBL] [Abstract][Full Text] [Related]
26. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
[TBL] [Abstract][Full Text] [Related]
27. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.
Afrin F; Rajesh R; Anam K; Gopinath M; Pal S; Ali N
Infect Immun; 2002 Dec; 70(12):6697-706. PubMed ID: 12438344
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
[TBL] [Abstract][Full Text] [Related]
30. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
Kaur J; Kaur T; Kaur S
Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
[TBL] [Abstract][Full Text] [Related]
31. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
Thakur A; Kaur H; Kaur S
Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
[TBL] [Abstract][Full Text] [Related]
32. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
[TBL] [Abstract][Full Text] [Related]
33. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
34. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
Henriquez FL; Campbell SA; Roberts CW; Mullen AB; Burchmore R; Carter KC
J Parasitol; 2010 Oct; 96(5):929-36. PubMed ID: 20950100
[TBL] [Abstract][Full Text] [Related]
35. Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection.
Bhowmick S; Mazumdar T; Ali N
Infect Immun; 2009 Apr; 77(4):1514-23. PubMed ID: 19168736
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages.
Shimizu Y; Takagi H; Nakayama T; Yamakami K; Tadakuma T; Yokoyama N; Kojima N
Parasite Immunol; 2007 May; 29(5):229-39. PubMed ID: 17430546
[TBL] [Abstract][Full Text] [Related]
37. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
38. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis.
Jaffe CL; Rachamim N; Sarfstein R
J Immunol; 1990 Jan; 144(2):699-706. PubMed ID: 2295807
[TBL] [Abstract][Full Text] [Related]
39. Effect of immunization with lipid associated polysaccharide antigen and anti CD-2 antibodies on class II MHC expression and cellular immune response in BALB/C mice infected with Leishmania donovani.
Bimal S; Bagchi AK; Das V; Sinha PK; Lal CS; Ranjan A; Gupta AK; Kar SK
Indian J Exp Biol; 2001 Sep; 39(9):878-82. PubMed ID: 11831368
[TBL] [Abstract][Full Text] [Related]
40. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
Russell DG; Alexander J
J Immunol; 1988 Feb; 140(4):1274-9. PubMed ID: 3257774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]